trending Market Intelligence /marketintelligence/en/news-insights/trending/oighgdrxvnpitctmahuxha2 content esgSubNav
In This List

Sun Pharmaceutical fiscal Q3'18 profit falls YOY


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Sun Pharmaceutical fiscal Q3'18 profit falls YOY

Sun Pharmaceutical Industries Ltd. posted a year-over-year drop in reported net profit for the third fiscal quarter of 2018, due to a one-time tax payout.

Adjusted net profit was 8.78 billion Indian rupees. Reported net profit for the period totaled 3.65 billion rupees, versus 14.72 billion rupees in the year-ago period.

Reported net profit was hit by a one-time deferred tax adjustment of 5.13 billion rupees due to changes in the U.S. tax rates.

The performance for the third fiscal quarter reflects a "gradual improvement in profitability over the first half of this year, despite a challenging U.S. generic pricing environment," Managing Director Dilip Shanghvi said.

Total revenue for the quarter was 66.53 billion rupees. Total sales in the period were 65.98 billion rupees, down 14% from the year-ago period.

EBITDA for the quarter was 13.98 billion rupees, resulting in an EBITDA margin of 21.2%.

Research and development investments for the period reached 4.73 billion rupees, compared with 6.13 billion rupees in the year-ago quarter.

As of Feb. 13, US$1 was equivalent to 64.27 Indian rupees.